Stock listing
Munich:CUP Chugai Pharmaceutical Co., Ltd. Aktie
German listing (Munich) of Chugai Pharmaceutical Co., Ltd. · home listing Tokyo:4519
Follow Chugai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · MUN:CUP
€40.08 EUR -1.67 (-4.0%)
Close on Nov 20, 2026
- Day range
- €40.08 – €40.64 EURNov 20, 2026
- Market cap
- €53.24B EURAt the close on Nov 20, 2026 · price × 1.33B shares outstanding
- 52-week range
- €34.05 – €57.20 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,742 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:CHGCY | $22.26 USD | -0.20 (-0.9%) | 218,409 | $22.81 | $22.81 | $22.01 | $22.46 | Close on Nov 20, 2026 |
| OTC:CHGCF | $44.81 USD | +0.488 (+1.1%) | 561 | $44.81 | $44.81 | $44.81 | $44.32 | Close on Nov 20, 2026 |
| Frankfurt:CUP | €40.51 EUR | -0.67 (-1.6%) | — | €40.54 | €40.65 | €40.51 | €41.18 | Close on Nov 20, 2026 |
| Munich:CUP | €40.08 EUR | -1.67 (-4.0%) | — | €40.64 | €40.64 | €40.08 | €41.75 | Close on Nov 20, 2026 |
| Dusseldorf:CUP | €39.61 EUR | -1.17 (-2.9%) | — | €40.09 | €40.58 | €39.61 | €40.78 | Close on Nov 20, 2026 |
| Frankfurt:CUP0 | €19.50 EUR | -0.40 (-2.0%) | — | €19.50 | €19.50 | €19.50 | €19.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · MUN:CUP · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €38.29 | -1.989 | -4.9% | €38.29 | €38.29 | €38.29 | 0 | |
| €40.28 | +1.019 | +2.6% | €40.28 | €40.28 | €40.28 | 0 | |
| €39.26 | +0.984 | +2.6% | €39.43 | €39.43 | €39.03 | 0 | |
| €38.27 | -0.157 | -0.4% | €38.29 | €38.60 | €38.11 | 0 | |
| €38.43 | -0.41 | -1.1% | €38.59 | €38.76 | €38.09 | 0 | |
| €38.84 | +1.358 | +3.6% | €38.84 | €38.84 | €38.82 | 0 | |
| €37.48 | -0.391 | -1.0% | €37.78 | €37.94 | €37.40 | 0 | |
| €37.87 | -0.226 | -0.6% | €37.87 | €37.87 | €37.87 | 0 | |
| €38.10 | -0.807 | -2.1% | €38.10 | €38.18 | €37.55 | 0 | |
| €38.91 | +0.568 | +1.5% | €38.91 | €38.91 | €38.91 | 1,300 | |
| €38.34 | +1.026 | +2.7% | €38.34 | €38.34 | €38.34 | 0 | |
| €37.31 | +0.685 | +1.9% | €37.31 | €37.31 | €37.31 | 0 | |
| €36.63 | +0.572 | +1.6% | €36.63 | €36.63 | €36.63 | 0 | |
| €36.05 | +0.488 | +1.4% | €35.99 | €36.16 | €35.92 | 0 | |
| €35.57 | -0.358 | -1.0% | €35.57 | €35.57 | €35.57 | 0 | |
| €35.92 | +0.522 | +1.5% | €35.93 | €36.05 | €35.74 | 0 | |
| €35.40 | +1.196 | +3.5% | €35.38 | €35.67 | €35.16 | 0 | |
| €34.21 | -0.485 | -1.4% | €34.21 | €34.47 | €34.05 | 0 | |
| €34.69 | +0.634 | +1.9% | €34.69 | €34.69 | €34.69 | 0 | |
| €34.06 | -0.078 | -0.2% | €34.06 | €34.06 | €34.06 | 0 | |
| €34.14 | -0.405 | -1.2% | €34.14 | €34.14 | €34.14 | 0 | |
| €34.54 | +0.054 | +0.2% | €34.54 | €34.54 | €34.54 | 0 | |
| €34.49 | +0.143 | +0.4% | €34.49 | €34.49 | €34.49 | 0 | |
| €34.34 | -0.105 | -0.3% | €34.34 | €34.34 | €34.34 | 0 | |
| €34.45 | +0.21 | +0.6% | €34.78 | €34.85 | €34.45 | 0 | |
| €34.24 | -0.14 | -0.4% | €34.24 | €34.24 | €34.24 | 0 | |
| €34.38 | -0.076 | -0.2% | €34.38 | €34.38 | €34.38 | 0 | |
| €34.45 | +0.024 | +0.1% | €34.45 | €34.45 | €34.45 | 0 | |
| €34.43 | -0.703 | -2.0% | €34.53 | €34.60 | €34.16 | 0 | |
| €35.13 | -1.751 | -4.7% | €35.31 | €35.66 | €35.12 | 0 | |
| €36.88 | +0.078 | +0.2% | €36.93 | €37.02 | €36.58 | 0 | |
| €36.81 | -0.475 | -1.3% | €36.81 | €36.81 | €36.81 | 0 | |
| €37.28 | +0.031 | +0.1% | €37.28 | €37.28 | €37.28 | 0 | |
| €37.25 | +0.064 | +0.2% | €37.25 | €37.25 | €37.25 | 0 | |
| €37.19 | +0.117 | +0.3% | €37.37 | €37.45 | €37.18 | 0 | |
| €37.07 | -0.283 | -0.8% | €37.16 | €37.21 | €36.98 | 4 | |
| €37.35 | +1.31 | +3.6% | €37.39 | €37.58 | €37.35 | 0 | |
| €36.04 | -0.347 | -1.0% | €36.04 | €36.04 | €36.04 | 0 | |
| €36.39 | +0.364 | +1.0% | €36.43 | €36.44 | €36.37 | 0 | |
| €36.03 | +0.227 | +0.6% | €36.22 | €36.40 | €36.01 | 0 | |
| €35.80 | +0.23 | +0.6% | €35.96 | €36.00 | €35.75 | 0 | |
| €35.57 | -0.841 | -2.3% | €35.67 | €36.07 | €35.55 | 0 | |
| €36.41 | -0.12 | -0.3% | €36.58 | €36.58 | €36.17 | 0 | |
| €36.53 | +0.182 | +0.5% | €36.75 | €36.78 | €36.33 | 0 | |
| €36.35 | -1.269 | -3.4% | €36.37 | €36.48 | €36.26 | 0 | |
| €37.62 | +0.276 | +0.7% | €37.63 | €37.63 | €37.34 | 0 | |
| €37.34 | +0.371 | +1.0% | €37.56 | €37.70 | €37.10 | 0 | |
| €36.97 | -0.24 | -0.6% | €37.04 | €37.31 | €36.91 | 0 | |
| €37.21 | -0.154 | -0.4% | €37.40 | €37.54 | €37.17 | 0 | |
| €37.36 | -0.874 | -2.3% | €37.46 | €37.68 | €37.34 | 1,300 | |
| €38.24 | +0.779 | +2.1% | €37.71 | €38.26 | €37.67 | 0 | |
| €37.46 | -0.597 | -1.6% | €37.47 | €37.48 | €37.45 | 0 | |
| €38.06 | +0.771 | +2.1% | €38.20 | €38.26 | €38.05 | 0 | |
| €37.28 | -0.692 | -1.8% | €37.31 | €37.35 | €37.25 | 0 | |
| €37.98 | +0.343 | +0.9% | €37.98 | €37.98 | €37.59 | 0 | |
| €37.63 | -0.736 | -1.9% | €37.76 | €37.92 | €37.63 | 0 | |
| €38.37 | +0.777 | +2.1% | €38.42 | €38.63 | €38.01 | 0 |
- Ticker
- Munich:CUP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Oct 27, 2026
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Latest earnings call · Jul 24, 2026
Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Oct 27, 2026
Closed €38.10 (-2.1%) on Oct 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
Oct 27, 2026
Closed €38.10 (-2.1%) on Oct 27, 2026
F. Hoffmann-La Roche Announces Third Quarter Sales 2026
Oct 22, 2026
Closed €37.31 (+1.9%) on Oct 22, 2026
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Sep 28, 2026
Closed €35.13 (-4.7%) on Sep 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Sep 9, 2026
Closed €36.41 (-0.3%) on Sep 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
Aug 18, 2026
Closed €37.40 (+0.4%) on Aug 18, 2026
Chugai Announces 2026 2nd Quarter Results
Jul 27, 2026
Closed €36.94 (-7.9%) on Jul 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Jul 24, 2026
Closed €40.10 (+4.8%) on Jul 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
Jul 23, 2026
Closed €38.27 (-3.0%) on Jul 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
Jun 22, 2026
Closed €40.39 (-1.2%) on Jun 22, 2026
Chugai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 31 in all · newest Oct 27, 2026 · oldest 2025
- Calls
- 9 calls with a replay · 9 with a transcript · latest Jul 24, 2026
- Decks
- 107 decks · latest Oct 27, 2026
Where Chugai Pharmaceutical Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4519 中外製薬 · Home listing | Tokyo | Japan | JPY |
| OTC:CHGCY | OTC | United States | USD |
| OTC:CHGCF | OTC | United States | USD |
| gettex:CUP | gettex | Germany | EUR |
| Frankfurt:CUP | Frankfurt | Germany | EUR |
| Tradegate:CUP | Tradegate | Germany | EUR |
| LS Exchange:857216 | LS Exchange | Germany | EUR |
| Lang & Schwarz:857216 | Lang & Schwarz | Germany | EUR |
| BMV:4519N | BMV | Mexico | MXN |
| Munich:CUP · This page | Munich | Germany | EUR |
| Stuttgart:CUP | Stuttgart | Germany | EUR |
| Hamburg:CUP | Hamburg | Germany | EUR |
| Dusseldorf:CUP | Dusseldorf | Germany | EUR |
| gettex:CUP0 | gettex | Germany | EUR |
| Hanover:CUP | Hanover | Germany | EUR |
| BIVA:4519N | BIVA | Mexico | MXN |
| Frankfurt:CUP0 | Frankfurt | Germany | EUR |
| Munich:CUP0 | Munich | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Osamu Okuda | Representative Director, President & CEO |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Hitoshi Iikura | Director, Executive Vice President |
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
Board
| Director | Role |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
| Hitoshi Iikura | Director, Executive Vice President |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) |
| Osamu Okuda | Representative Director, President & CEO |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) |
| Teresa A. Graham | Director |
| Thomas Schinecker | Director |
Events
| Call | When | Status |
|---|---|---|
| Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 3:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2026 Earnings Call | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2025 Earnings Call | Thu, Jan 29, 2026 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2025 Earnings Call | Sat, Oct 25, 2025 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2024 Earnings Call | Thu, Jan 30, 2025 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2024 Earnings Call | Fri, Oct 25, 2024 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2024 Earnings Call | Wed, Apr 24, 2024 · 5:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Technical Presentation (June 2026) | Technical | 45 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | Apr 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 53 slides | Jan 29, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 47 slides | Jul 24, 2025 |
| souzoulabo slide | 6 slides | February 2025 | |
| FY2024 Earnings Presentation | Earnings | 56 slides | Jan 30, 2025 |
Show 50 decks
This page holds 50 of 107 decks. Open Decks
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
Cap table
Built by 6ix from Chugai Pharmaceutical Co., Ltd.’s releases
- Common shares
- 1,679,057,667
- Fully diluted
- 1,679,057,667
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,679,057,667 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,679,057,667 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche · Since at least Mar 27, 2026 |
| Hitoshi Iikura | Director, Executive Vice President · Since at least Mar 27, 2026 |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO · Since at least Mar 27, 2026 |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Osamu Okuda | Representative Director, President & CEO · Since at least Sep 9, 2026 |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Teresa A. Graham | Director · Since at least Mar 27, 2026 |
| Thomas Schinecker | Director · Since at least Mar 27, 2026 |
Log in to ask 6ix AI your own questions about Chugai Pharmaceutical Co., Ltd.